MultiCell Technologies Inc (MCET)

[ricardoman]

Richard L. Klein new President of MCET subsidiary Xenogenics Corp was the founder of Medlogics Device Corporation. Medlogics has the COBRA stent (a physical stent). In 2008 they (Medlogics) licensed CV Therapeutics' "biopolymer stent coating technology". Shortly thereafter, CV Therapeutics got acquired by Gilead Sciences. Did that shelf the agreement? Don't know, but a subsequent scan of Gilead's recent 10K reveals nothing further related to the Medlogics license. So, could be that Multicell's "ideal Biostent" (patented coating) has something Medlogics might now be interested in. This is just a wild guess of course. It is interesting, however, that the founder of Medlogics- is now the President of Xenogenics- that seeks to develop their patented "Ideal Biostent".

http://www.crtonline.org/pr.aspx?PAGE_ID=4954

Some info on COBRA and comments/insight from Klein on the COBRA stent and coated stent technology from 2008.

http://www.theheart.org/documents/sitestructure/en/content/press-center/PDF/clintrial.pdf